Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.

The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.

The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.

Primary and secondary endpoint results in “Supplements, Placebo, or Rosuvastatin” study conducted by Cleveland Clinic include no difference, after four weeks, in total cholesterol and blood triglyceride measures between subjects receiving placebo and those using fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice.